BioCryst Pharmaceuticals | BCRX - 销售和管理费用

金融业

USD

USD 465.05M

现金及等价物

USD 171.59M

USD 9.52M

USD 373.63M

USD 195.39M

USD 828.6M

股息收益率

0

USD 260.39M

USD 51.7M

536

EPS每股收益

USD 1.17

股本和储备

USD -553.84M

USD 153.05M

债务利息支出

USD 14.14M

USD -0.13

USD 395.2M

USD 2.05B

USD 245.85M

USD -553.84M

USD 260.39M

普通股股本

USD 213.06M

6.06

USD 248.02M

USD 406.56M

销售和管理费用

USD 95.78M

USD 5.99M

贸易债权人

USD 10.96M

应收帐款人

USD 106.82M

	销售和管理费用	更改		日
Alnylam Pharmaceuticals	USD 282.51M		2.55M	2026-03
BioCryst Pharmaceuticals	USD 95.78M		12.77M	2025-12
Chugai Pharma	JPY 28.9B		8.02B	2026-03
Daiichi Sankyo	JPY 228.23B		39.15B	2025-12
DBV Technologies	USD 13.4M		8.14M	2026-03
Enanta Pharmaceuticals	USD -1.05		0.31	2024-12
Gilead Sciences	USD 1.45B		326M	2026-03
GlaxoSmithKline	GBP 2.12B		558M	2026-03
Glaxosmithkline	GBP 2.12B		1.44B	2026-03
Incyte	USD 328.1M		62.31M	2026-03
Ionis Pharmaceuticals	USD 151M		21M	2026-03
Karyopharm Therapeutics	USD 9.56M		17.63M	2025-12
Neurocrine Biosciences	USD 318.5M		16.7M	2026-03
Novavax	USD 25.53M		1.34M	2025-12
PTC Therapeutics	USD 73.89M		13.31M	2026-03
Regeneron Pharmaceuticals	USD 647.7M		127.3M	2026-03
Roche Holding	CHF 7.28B		3.99B	2025-12
Sarepta Therapeutics	USD 54.03M		51.35M	2026-03
Ultragenyx Pharmaceutical	USD 88M		1000K	2026-03
Vertex Pharmaceuticals	USD 493.7M		6.7M	2026-03